Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase

Oncogenic FLT3 kinase is a clinically validated target in acute myeloid leukemia (AML), and both multi-targeted and selective FLT3 inhibitors have been developed. Spleen tyrosine kinase (SYK) has been shown to be activated and increased in FLT3-ITD-positive AML patients, and has further been shown t...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Weisberg, Ellen L., Puissant, Alexandre, Stone, Richard, Sattler, Martin, Buhrlage, Sara J., Yang, Jing, Manley, Paul W., Meng, Chengcheng, Buonopane, Michael, Daley, John F., Lazo, Suzan, Wright, Renee, Weinstock, David M., Christie, Amanda L., Stegmaier, Kimberly, Griffin, James D.
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Priority Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581010/
https://ncbi.nlm.nih.gov/pubmed/28881711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19036
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky